Oncology Rehabilitation

  • Julie K. SilverEmail author
  • Vishwa S. Raj
  • Eric M. Wisotzky


Oncology rehabilitation is an expanding field of medical care focused on preparing the cancer patient for upcoming cancer treatment (prehabilitation); maintaining patient strength, functioning and quality of life during cancer treatment; and helping patients either recover strength, functioning, and quality of life following cancer treatment or adjust to the long-term sequelae associated with their cancer or cancer-related treatments. This chapter addresses how rehabilitation interventions (1) fit into the continuum of cancer care; (2) can be used to address cancer and cancer treatment-related side effects such as pain, fatigue, lymphedema, cognitive dysfunction, and bone issues; and (3) can be used in cases of specific cancer diagnoses including, but not limited to breast, lung, prostate, colorectal, head and neck, and hematologic cancers.


Cancer Oncology Prehabilitation Rehabilitation Acute care Post-acute care Cancer-related Impairment Pain Fatigue Lymphedema Cognitive dysfunction Bone Breast Lung Prostate Colorectal Head and neck Hematologic Stem cell transplantation 



Aromatase inhibitor-induced musculoskeletal symptoms


Acute lymphoblastic leukemia


Axillary lymph node dissection


Acute myeloid leukemia


Complete decongestive therapy


Chemotherapy-induced peripheral neuropathy


Chronic lymphocytic leukemia


Chronic myeloid leukemia


Commission on Cancer


Chronic obstructive pulmonary disease


Computed tomography


Ewing’s sarcoma


Forced vital capacity


Graft-versus-host disease


Home health agencies


Hodgkin’s lymphoma


International Classification of Functioning, Disability and Health


Intensive care unit


Inpatient rehabilitation facilities


Length of stays


Long-term acute care hospitals


Long-term care hospitals


Mild cognitive impairment


Multiple myeloma


Magnetic resonance imaging


National Accreditation Program for Breast Centers


National Cancer Institute


National Center for Medical Rehabilitation Research


Non-Hodgkin’s lymphoma


National Institutes of Health


Non-small cell lung carcinoma


Occupational therapy


Post-acute care


Prostate-specific antigen


Physical therapists


Quality of life


Radiation therapy


Stem cell transplantation


Sentinel lymph node biopsy


Speech and language pathology services


Skilled nursing facilities


Serotonin and norepinephrine reuptake inhibitors


Tyrosine kinase inhibitors


Transcutaneous nerve stimulation


World Health Organization


  1. 1.
    Silver JK, Raj VS, Fu JB, Wisotzky EM, Smith SR, Kirch RA. Cancer rehabilitation and palliative care: critical components in the delivery of high-quality oncology services. Support Care Cancer. 2015;23:3633–43.PubMedCrossRefGoogle Scholar
  2. 2.
    Silver JK, Baima J, Mayer RS. Impairment-driven cancer rehabilitation: an essential component of quality care and survivorship. CA Cancer J Clin. 2013;63:295–317.PubMedCrossRefGoogle Scholar
  3. 3.
    Silver JK, Raj VS, Fu JB, Wisotzky EM, Smith SR, Knowlton SE, et al. Most national cancer institute-designated cancer center websites do not provide survivors with information about cancer rehabilitation services. J Cancer Educ. 2017. Accessed 20 June 2017.
  4. 4.
    Stout NL, Silver JK, Raj VS, Rowland J, Gerber L, Cheville A, et al. Toward a national initiative in cancer rehabilitation: recommendations from a subject matter expert group. Arch Phys Med Rehabil. 2016;97:2006–15.PubMedCrossRefGoogle Scholar
  5. 5.
    Broadwell DC. Rehabilitation needs of the patient with cancer. Cancer. 1987;60:563–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Driessen EJ, Peeters ME, Bongers BC, Maas HA, Bootsma GP, van Meeteren NL, et al. Effects of prehabilitation and rehabilitation including a home-based component on physical fitness, adherence, treatment tolerance, and recovery in patients with non-small cell lung cancer: a systematic review. Crit Rev Oncol Hematol. 2017;114:63–76.PubMedCrossRefGoogle Scholar
  7. 7.
    Onerup A, Angenete E, Bock D, Borjesson M, Fagevik Olsen M, Gryback Gillheimer E, et al. The effect of pre- and post-operative physical activity on recovery after colorectal cancer surgery (physsurg-c): study protocol for a randomised controlled trial. Trials. 2017;18:212.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Minnella EM, Bousquet-Dion G, Awasthi R, Scheede-Bergdahl C, Carli F. Multimodal prehabilitation improves functional capacity before and after colorectal surgery for cancer: a five-year research experience. Acta Oncol. 2017;56:295–300.PubMedCrossRefGoogle Scholar
  9. 9.
    Carli F, Gillis C, Scheede-Bergdahl C. Promoting a culture of prehabilitation for the surgical cancer patient. Acta Oncol. 2017;56:128–33.PubMedCrossRefGoogle Scholar
  10. 10.
    Masley PM, Havrilko CL, Mahnensmith MR, Aubert M, Jette DU. Physical therapist practice in the acute care setting: a qualitative study. Phys Ther. 2011;91:906–19.PubMedCrossRefGoogle Scholar
  11. 11.
    Smith BA, Fields CJ, Fernandez N. Physical therapists make accurate and appropriate discharge recommendations for patients who are acutely ill. Phys Ther. 2010;90:693–703.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Malone D, Ridgeway K, Nordon-Craft A, Moss P, Schenkman M, Moss M. Physical therapist practice in the intensive care unit: results of a national survey. Phys Ther. 2015;95:1335–44.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Burtin C, Clerckx B, Robbeets C, Ferdinande P, Langer D, Troosters T, et al. Early exercise in critically ill patients enhances short-term functional recovery. Crit Care Med. 2009;37:2499–505.PubMedCrossRefGoogle Scholar
  14. 14.
    Mechanic R. Post-acute care--the next frontier for controlling medicare spending. N Engl J Med. 2014;370:692–4.PubMedCrossRefGoogle Scholar
  15. 15.
    Inpatient rehabilitation therapy services: Complying with documentation requirements. Department Of Health and Human Services, Centers for Medicare & Medicaid Services. 2012. Accessed 30 Apr 2017.
  16. 16.
    Shay PD, Ozcan YA. Freestanding inpatient rehabilitation facility performance following the 60 percent rule: a matter of fit. Med Care Res Rev. 2013;70:46–67.PubMedCrossRefGoogle Scholar
  17. 17.
    Inpatient rehabilitation facility prospective payment system. Department of Health and Human Services, Center for Medicare & Medicaid Services. 2017. Accessed 30 April 2017.
  18. 18.
    Goldberg TH. The long-term and post-acute care continuum. W V Med J. 2016;112:68–74.PubMedGoogle Scholar
  19. 19.
    Coverage of extended care (snf) services under hospital insurance. Medicare Benefit Policy Manual. Rev 228, 10–13-16. Centers for Medicare & Medicaid Services. 2016. Accessed 24 April 2017.
  20. 20.
    Eskildsen MA. Long-term acute care: a review of the literature. J Am Geriatr Soc. 2007;55:775–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Kahn JM, Werner RM, David G, Ten Have TR, Benson NM, Asch DA. Effectiveness of long-term acute care hospitalization in elderly patients with chronic critical illness. Med Care. 2013;51:4–10.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Long term care hospital prospective payment system. Department Of Health and Human Services, Centers for Medicare & Medicaid Services. 2016. Accessed 28 April 2017.
  23. 23.
    Ellenbecker CH, Samia L, Cushman MJ, Alster K. Patient safety and quality in home health care. In: Hughes R, editor. Patient safety and quality: an evidence-based handbook for nurses. Rockville, MD: Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services; 2008. Accessed 12 Jun 2017.Google Scholar
  24. 24.
    U.S. Centers for Medicare & Medicaid Services. Your medicare coverage - home health services. Accessed 26 April 2017.
  25. 25.
    U.S. Centers for Medicare & Medicaid Services. Outpatient rehabilitation providers. 2013. Accessed 1 May 2017.
  26. 26.
    U.S. Centers for Medicare & Medicaid Services. Your medicare coverage - physical therapy/occupational therapy/speech-language pathology services. Accessed 1 May 2017.
  27. 27.
    U.S. Centers for Medicare & Medicaid Services. Medicare limits on therapy services. 2017. Accessed 1 May 2017.
  28. 28.
    Silver JK. Cancer rehabilitation and prehabilitation may reduce disability and early retirement. Cancer. 2014;120:2072–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Silver J, Mayer RS. Barriers to pain management in the rehabilitation of the surgical oncology patient. J Surg Oncol. 2007;95:427–35.PubMedCrossRefGoogle Scholar
  30. 30.
    Cancer pain relief: With a guide to opioid availability. 2nd ed. Geneva, Switzerland: World Health Organization; 1996.Google Scholar
  31. 31.
    Spiegel D, Bloom JR. Group therapy and hypnosis reduce metastatic breast carcinoma pain. Psychosom Med. 1983;45:333–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Buffart LM, Kalter J, Sweegers MG, Courneya KS, Newton RU, Aaronson NK, et al. Effects and moderators of exercise on quality of life and physical function in patients with cancer: an individual patient data meta-analysis of 34 rcts. Cancer Treat Rev. 2017;52:91–104.CrossRefPubMedGoogle Scholar
  33. 33.
    Carli F, Silver JK, Feldman LS, McKee A, Gilman S, Gillis C, et al. Surgical prehabilitation in patients with cancer: state-of-the-science and recommendations for future research from a panel of subject matter experts. Phys Med Rehabil Clin N Am. 2017;28:49–64.PubMedCrossRefGoogle Scholar
  34. 34.
    Stigt JA, Uil SM, van Riesen SJ, Simons FJ, Denekamp M, Shahin GM, et al. A randomized controlled trial of postthoracotomy pulmonary rehabilitation in patients with resectable lung cancer. J Thorac Oncol. 2013;8:214–21.PubMedCrossRefGoogle Scholar
  35. 35.
    Streckmann F, Zopf EM, Lehmann HC, May K, Rizza J, Zimmer P, et al. Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med. 2014;44:1289–304.PubMedCrossRefGoogle Scholar
  36. 36.
    Takamura Y, Miyauchi A, Tomoda C, Uruno T, Ito Y, Miya A, et al. Stretching exercises to reduce symptoms of postoperative neck discomfort after thyroid surgery: prospective randomized study. World J Surg. 2005;29:775–9.PubMedCrossRefGoogle Scholar
  37. 37.
    McNeely ML, Parliament M, Courneya KS, Seikaly H, Jha N, Scrimger R, et al. A pilot study of a randomized controlled trial to evaluate the effects of progressive resistance exercise training on shoulder dysfunction caused by spinal accessory neurapraxia/neurectomy in head and neck cancer survivors. Head Neck. 2004;26:518–30.PubMedCrossRefGoogle Scholar
  38. 38.
    Hase K, Kamisako M, Fujiwara T, Tsuji T, Liu M. The effect of zaltoprofen on physiotherapy for limited shoulder movement in breast cancer patients: a single-blinded before-after trial. Arch Phys Med Rehabil. 2006;87:1618–22.PubMedCrossRefGoogle Scholar
  39. 39.
    Searle RD, Bennett MI, Johnson MI, Callin S, Radford H. Transcutaneous electrical nerve stimulation (tens) for cancer bone pain. J Pain Symptom Manag. 2009;37:424–8.CrossRefGoogle Scholar
  40. 40.
    Cristian A, Tran A, Patel K. Patient safety in cancer rehabilitation. Phys Med Rehabil Clin N Am. 2012;23:441–56.PubMedCrossRefGoogle Scholar
  41. 41.
    Paice JA, Portenoy R, Lacchetti C, Campbell T, Cheville A, Citron M, et al. Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:3325–45.PubMedCrossRefGoogle Scholar
  42. 42.
    Grunfeld EA, Cooper AF. A longitudinal qualitative study of the experience of working following treatment for gynaecological cancer. Psychooncology. 2012;21:82–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Nccn clinical practice guidelines in oncology: Cancer-related fatigue. Version 1.2009. Rockledge, PA: National Comprehensive Cancer Network; 2009.Google Scholar
  44. 44.
    Dimeo FC. Effects of exercise on cancer-related fatigue. Cancer. 2001;92:1689–93.PubMedCrossRefGoogle Scholar
  45. 45.
    Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. International chronic fatigue syndrome study group. Ann Intern Med. 1994;121:953–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Gerber LH. Cancer-related fatigue: persistent, pervasive, and problematic. Phys Med Rehabil Clin N Am. 2017;28:65–88.PubMedCrossRefGoogle Scholar
  47. 47.
    Juvet LK, Thune I, Elvsaas IKO, Fors EA, Lundgren S, Bertheussen G, et al. The effect of exercise on fatigue and physical functioning in breast cancer patients during and after treatment and at 6 months follow-up: a meta-analysis. Breast. 2017;33:166–77.PubMedCrossRefGoogle Scholar
  48. 48.
    Twomey R, Aboodarda SJ, Kruger R, Culos-Reed SN, Temesi J, Millet GY. Neuromuscular fatigue during exercise: methodological considerations, etiology and potential role in chronic fatigue. Neurophysiol Clin. 2017;47:95–110.PubMedCrossRefGoogle Scholar
  49. 49.
    Keilani M, Hasenoehrl T, Baumann L, Ristl R, Schwarz M, Marhold M, et al. Effects of resistance exercise in prostate cancer patients: a meta-analysis. Support Care Cancer. 2017 Sep;25(9):2953–68.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Miller CL, Specht MC, Skolny MN, Horick N, Jammallo LS, O'Toole J, et al. Risk of lymphedema after mastectomy: potential benefit of applying acosog z0011 protocol to mastectomy patients. Breast Cancer Res Treat. 2014;144:71–7.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Jensen MR, Simonsen L, Karlsmark T, Bulow J. Lymphoedema of the lower extremities--background, pathophysiology and diagnostic considerations. Clin Physiol Funct Imaging. 2010;30:389–98.PubMedCrossRefGoogle Scholar
  52. 52.
    NABPC Standards Manual. 2014 ed. Chicago, IL: American College of Surgeons; 2014.Google Scholar
  53. 53.
    Norman SA, Localio AR, Potashnik SL, Simoes Torpey HA, Kallan MJ, Weber AL, et al. Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol. 2009;27:390–7.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Cheville AL, McGarvey CL, Petrek JA, Russo SA, Thiadens SR, Taylor ME. The grading of lymphedema in oncology clinical trials. Semin Radiat Oncol. 2003;13:214–25.PubMedCrossRefGoogle Scholar
  55. 55.
    Stout NL, Pfalzer LA, Springer B, Levy E, McGarvey CL, Danoff JV, et al. Breast cancer-related lymphedema: comparing direct costs of a prospective surveillance model and a traditional model of care. Phys Ther. 2012;92:152–63.PubMedCrossRefGoogle Scholar
  56. 56.
    Ferguson CM, Swaroop MN, Horick N, Skolny MN, Miller CL, Jammallo LS, et al. Impact of ipsilateral blood draws, injections, blood pressure measurements, and air travel on the risk of lymphedema for patients treated for breast cancer. J Clin Oncol. 2016;34:691–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Cemal Y, Pusic A, Mehrara BJ. Preventative measures for lymphedema: separating fact from fiction. J Am Coll Surg. 2011;213:543–51.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Schmitz KH, Ahmed RL, Troxel A, Cheville A, Smith R, Lewis-Grant L, et al. Weight lifting in women with breast-cancer-related lymphedema. N Engl J Med. 2009;361:664–73.PubMedCrossRefGoogle Scholar
  59. 59.
    Bergo E, Lombardi G, Pambuku A, Della Puppa A, Bellu L, D'Avella D, et al. Cognitive rehabilitation in patients with gliomas and other brain tumors: state of the art. Biomed Res Int. 2016;2016:3041824.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Vargo M, Henriksson R, Salander P. Rehabilitation of patients with glioma. Handb Clin Neurol. 2016;134:287–304.PubMedCrossRefGoogle Scholar
  61. 61.
    Haskins EC. Cognitive rehabilitation manual: translating evidence-based recommendations into practice. 1st ed. Reston, VA: American Congress of Rehabilitation Medicine; 2012.Google Scholar
  62. 62.
    Bush SH, Kanji S, Pereira JL, Davis DH, Currow DC, Meagher DJ, et al. Treating an established episode of delirium in palliative care: expert opinion and review of the current evidence base with recommendations for future development. J Pain Symptom Manag. 2014;48:231–48.CrossRefGoogle Scholar
  63. 63.
    Zimmer P, Baumann FT, Oberste M, Wright P, Garthe A, Schenk A, et al. Effects of exercise interventions and physical activity behavior on cancer related cognitive impairments: a systematic review. Biomed Res Int. 2016;2016:1820954.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Dai X, Ma W, He X, Jha RK. Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and ewing's sarcoma. Med Sci Monit. 2011;17:RA177–90.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3–13.PubMedCrossRefGoogle Scholar
  66. 66.
    Tiwari A. Current concepts in surgical treatment of osteosarcoma. J Clin Ortho Trauma. 2012;3:4–9.CrossRefGoogle Scholar
  67. 67.
    Schwarz R, Bruland O, Cassoni A, Schomberg P, Bielack S. The role of radiotherapy in oseosarcoma. Cancer Treat Res. 2009;152:147–64.PubMedCrossRefGoogle Scholar
  68. 68.
    Andreou D, Ruppin S, Fehlberg S, Pink D, Werner M, Tunn PU. Survival and prognostic factors in chondrosarcoma: results in 115 patients with long-term follow-up. Acta Orthop. 2011;82:749–55.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Gelderblom H, Hogendoorn PC, Dijkstra SD, van Rijswijk CS, Krol AD, Taminiau AH, et al. The clinical approach towards chondrosarcoma. Oncologist. 2008;13:320–9.PubMedCrossRefGoogle Scholar
  70. 70.
    Rani PS, Shyamala K, Girish HC, Murgod S. Pathogenesis of Ewing sarcoma: a review. J Adv Clin Res Insights. 2015;2:164–8.CrossRefGoogle Scholar
  71. 71.
    Ozaki T. Diagnosis and treatment of Ewing sarcoma of the bone: a review article. J Orthop Sci. 2015;20:250–63.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Suva LJ, Washam C, Nicholas RW, Griffin RJ. Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol. 2011;7:208–18.PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Jawad MU, Scully SP. In brief: classifications in brief: Mirels' classification: metastatic disease in long bones and impending pathologic fracture. Clin Orthop Relat Res. 2010;468:2825–7.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Shapeero LG, Poffyn B, De Visschere PJ, Sys G, Uyttendaele D, Vanel D, et al. Complications of bone tumors after multimodal therapy. Eur J Radiol. 2011;77:51–67.PubMedCrossRefGoogle Scholar
  75. 75.
    Fukumothi DK, Pupo H, Reganin LA, Matte SR, Lima BS, Mattos CA. Functional assessment of endoprosthesis in the treatment of bone tumors. Rev Bras Ortop. 2016;51:569–73.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Fauske L, Bruland OS, Grov EK, Bondevik H. Cured of primary bone cancer, but at what cost: a qualitative study of functional impairment and lost opportunities. Sarcoma. 2015;2015:484196.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Dieli-Conwright CM, Lee K, Kiwata JL. Reducing the risk of breast cancer recurrence: an evaluation of the effects and mechanisms of diet and exercise. Curr Breast Cancer Rep. 2016;8:139–50.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Wennman-Larsen A, Alexanderson K, Olsson M, Nilsson MI, Petersson LM. Sickness absence in relation to breast and arm symptoms shortly after breast cancer surgery. Breast. 2013;22:767–72.PubMedCrossRefGoogle Scholar
  79. 79.
    Torres Lacomba M, Mayoral del Moral O, Coperias Zazo JL, Gerwin RD, Goni AZ. Incidence of myofascial pain syndrome in breast cancer surgery: a prospective study. Clin J Pain. 2010;26:320–5.PubMedCrossRefGoogle Scholar
  80. 80.
    Yang S, Park DH, Ahn SH, Kim J, Lee JW, Han JY, et al. Prevalence and risk factors of adhesive capsulitis of the shoulder after breast cancer treatment. Support Care Cancer. 2017;25:1317–22.PubMedCrossRefGoogle Scholar
  81. 81.
    Crosbie J, Kilbreath SL, Dylke E, Refshauge KM, Nicholson LL, Beith JM, et al. Effects of mastectomy on shoulder and spinal kinematics during bilateral upper-limb movement. Phys Ther. 2010;90:679–92.PubMedCrossRefGoogle Scholar
  82. 82.
    Stubblefield MD, Keole N. Upper body pain and functional disorders in patients with breast cancer. PM R. 2014;6:170–83.PubMedCrossRefGoogle Scholar
  83. 83.
    Wisotzky EM, Saini V, Kao C. Ultrasound-guided intercostobrachial nerve block for intercostobrachial neuralgia in breast cancer patients: a case series. PM R. 2016;8:273–7.PubMedCrossRefGoogle Scholar
  84. 84.
    Zocca JA, Chen GH, Puttanniah VG, Hung JC, Gulati A. Ultrasound-guided serratus plane block for treatment of postmastectomy pain syndromes in breast cancer patients: a case series. Pain Pract. 2017;17:141–6.PubMedCrossRefGoogle Scholar
  85. 85.
    Tang C, Eder S, Lee D, Rabow M, Esserman L. Abstract p3-10-03: a simple intervention to relieve chronic neuropathic post-mastectomy pain. Cancer Res 2013;73.CrossRefGoogle Scholar
  86. 86.
    Kudlowitz D, Muggia F. Clinical features of taxane neuropathy. Anti-Cancer Drugs. 2014;25:495–501.PubMedCrossRefGoogle Scholar
  87. 87.
    Stubblefield MD, McNeely ML, Alfano CM, Mayer DK. A prospective surveillance model for physical rehabilitation of women with breast cancer: chemotherapy-induced peripheral neuropathy. Cancer. 2012;118:2250–60.PubMedCrossRefGoogle Scholar
  88. 88.
    Gaillard S, Stearns V. Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res. 2011;13:205.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25:3877–83.PubMedCrossRefGoogle Scholar
  90. 90.
    Kirchgesner T, Larbi A, Omoumi P, Malghem J, Zamali N, Manelfe J, et al. Drug-induced tendinopathy: from physiology to clinical applications. Joint Bone Spine. 2014;81:485–92.PubMedCrossRefGoogle Scholar
  91. 91.
    Irwin ML, Cartmel B, Gross CP, Ercolano E, Li F, Yao X, et al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol. 2015;33:1104–11.PubMedCrossRefGoogle Scholar
  92. 92.
    Crew KD, Capodice JL, Greenlee H, Brafman L, Fuentes D, Awad D, et al. Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol. 2010;28:1154–60.PubMedCrossRefGoogle Scholar
  93. 93.
    Henry NL, Banerjee M, Wicha M, Van Poznak C, Smerage JB, Schott AF, et al. Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms. Cancer. 2011;117:5469–75.PubMedCrossRefGoogle Scholar
  94. 94.
    Greenlee H, Crew KD, Shao T, Kranwinkel G, Kalinsky K, Maurer M, et al. Phase ii study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer. Support Care Cancer. 2013;21:1077–87.PubMedCrossRefGoogle Scholar
  95. 95.
    Kubo M, Onishi H, Kuroki S, Okido M, Shimada K, Yokohata K, et al. Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer. Anticancer Res. 2012;32:2331–6.PubMedGoogle Scholar
  96. 96.
    Singer O, Cigler T, Moore AB, Levine AB, Do HT, Mandl LA. Hypovitaminosis d is a predictor of aromatase inhibitor musculoskeletal symptoms. Breast J. 2014;20:174–9.PubMedCrossRefGoogle Scholar
  97. 97.
    Hung R, Krebs P, Coups EJ, Feinstein MB, Park BJ, Burkhalter J, et al. Fatigue and functional impairment in early-stage non-small cell lung cancer survivors. J Pain Symptom Manag. 2011;41:426–35.CrossRefGoogle Scholar
  98. 98.
    Shannon VR. Role of pulmonary rehabilitation in the management of patients with lung cancer. Curr Opin Pulm Med. 2010;16:334–9.PubMedCrossRefPubMedCentralGoogle Scholar
  99. 99.
    Bayly JL, Lloyd-Williams M. Identifying functional impairment and rehabilitation needs in patients newly diagnosed with inoperable lung cancer: a structured literature review. Support Care Cancer. 2016;24:2359–79.PubMedCrossRefGoogle Scholar
  100. 100.
    Cavalheri V, Granger C. Preoperative exercise training for patients with non-small cell lung cancer. Cochrane Database Syst Rev. 2017;6:CD012020.PubMedGoogle Scholar
  101. 101.
    Wang H, Liu X, Rice SJ, Belani CP. Pulmonary rehabilitation in lung cancer. PM R. 2016;8:990–6.PubMedCrossRefGoogle Scholar
  102. 102.
    Edvardsen E, Skjonsberg OH, Holme I, Nordsletten L, Borchsenius F, Anderssen SA. High-intensity training following lung cancer surgery: a randomised controlled trial. Thorax. 2015;70:244–50.PubMedCrossRefGoogle Scholar
  103. 103.
    Centers for Disease Control and Prevention. Cancer among men. 2016. Accessed 18 June 2017.
  104. 104.
    Attard G, Parker C, Eeles RA, Schroder F, Tomlins SA, Tannock I, et al. Prostate cancer. Lancet. 2016;387:70–82.PubMedCrossRefGoogle Scholar
  105. 105.
    Michaelson MD, Cotter SE, Gargollo PC, Zietman AL, Dahl DM, Smith MR. Management of complications of prostate cancer treatment. CA Cancer J Clin. 2008;58:196–213.PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    Simoneau AR. Treatment- and disease-related complications of prostate cancer. Rev Urol. 2006;8(Suppl 2):S56–67.PubMedPubMedCentralGoogle Scholar
  107. 107.
    Chen RC, Hamstra DA, Sandler HM, Zietman AL. Complications of prostate cancer treatment. Lancet Oncol. 2014;15:e150.PubMedCrossRefGoogle Scholar
  108. 108.
    Luo HC, Lei Y, Cheng HH, Fu ZC, Liao SG, Feng J, et al. Long-term cancer-related fatigue outcomes in patients with locally advanced prostate cancer after intensity-modulated radiotherapy combined with hormonal therapy. Medicine. 2016;95:e3948.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin. 2009;59:366–78.PubMedCrossRefGoogle Scholar
  110. 110.
    Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544–73.PubMedPubMedCentralCrossRefGoogle Scholar
  111. 111.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefGoogle Scholar
  112. 112.
    Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383:1490–502.PubMedCrossRefGoogle Scholar
  113. 113.
    Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004;101:3–27.PubMedCrossRefGoogle Scholar
  114. 114.
    Schneider EC, Malin JL, Kahn KL, Ko CY, Adams J, Epstein AM. Surviving colorectal cancer: patient-reported symptoms 4 years after diagnosis. Cancer. 2007;110:2075–82.PubMedCrossRefGoogle Scholar
  115. 115.
    Grosso G, Biondi A, Marventano S, Mistretta A, Calabrese G, Basile F. Major postoperative complications and survival for colon cancer elderly patients. BMC Surg. 2012;12(Suppl 1):S20.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Lange MM, Maas CP, Marijnen CA, Wiggers T, Rutten HJ, Kranenbarg EK, et al. Urinary dysfunction after rectal cancer treatment is mainly caused by surgery. Br J Surg. 2008;95:1020–8.PubMedCrossRefGoogle Scholar
  117. 117.
    Denlinger CS, Barsevick AM. The challenges of colorectal cancer survivorship. J Natl Compr Cancer Netw. 2009;7:883–93; quiz 94CrossRefGoogle Scholar
  118. 118.
    Baxter NN, Habermann EB, Tepper JE, Durham SB, Virnig BA. Risk of pelvic fractures in older women following pelvic irradiation. JAMA. 2005;294:2587–93.PubMedCrossRefGoogle Scholar
  119. 119.
    Vardy JL, Dhillon HM, Pond GR, Rourke SB, Bekele T, Renton C, et al. Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol. 2015;33:4085–92.PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Henry M, Rosberger Z, Bertrand L, Klassen C, Hier M, Zeitouni A, et al. Suicidal ideations are prevalent in head and neck cancer patients and predate diagnosis: longitudinal study indicating the need for suicide prevention and collaborative care in ent clinics. Psychooncology. 2017;26:46.Google Scholar
  121. 121.
    Heckmann SM, Hujoel P, Habiger S, Friess W, Wichmann M, Heckmann JG, et al. Zinc gluconate in the treatment of dysgeusia--a randomized clinical trial. J Dent Res. 2005;84:35–8.PubMedCrossRefGoogle Scholar
  122. 122.
    Dijkstra PU, Huisman PM, Roodenburg JL. Criteria for trismus in head and neck oncology. Int J Oral Maxillofac Surg. 2006;35:337–42.PubMedCrossRefGoogle Scholar
  123. 123.
    Stubblefield MD, Manfield L, Riedel ER. A preliminary report on the efficacy of a dynamic jaw opening device (dynasplint trismus system) as part of the multimodal treatment of trismus in patients with head and neck cancer. Arch Phys Med Rehabil. 2010;91:1278–82.PubMedCrossRefGoogle Scholar
  124. 124.
    National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts: Hodgkin lymphoma. Accessed 18 June 2017.
  125. 125.
    Gobbi PG, Ferreri AJ, Ponzoni M, Levis A. Hodgkin lymphoma. Crit Rev Oncol Hematol. 2013;85:216–37.PubMedCrossRefGoogle Scholar
  126. 126.
    Shankland KR, Armitage JO, Hancock BW. Non-hodgkin lymphoma. Lancet. 2012;380:848–57.PubMedCrossRefGoogle Scholar
  127. 127.
    Zimmermann M, Oehler C, Mey U, Ghadjar P, Zwahlen DR. Radiotherapy for non-hodgkin's lymphoma: still standard practice and not an outdated treatment option. Radiat Oncol. 2016;11:110.PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Ng AK, LaCasce A, Travis LB. Long-term complications of lymphoma and its treatment. J Clin Oncol. 2011;29:1885–92.PubMedCrossRefGoogle Scholar
  129. 129.
    Zimmer P, Mierau A, Bloch W, Struder HK, Hulsdunker T, Schenk A, et al. Post-chemotherapy cognitive impairment in patients with b-cell non-hodgkin lymphoma: a first comprehensive approach to determine cognitive impairments after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone or rituximab and bendamustine. Leuk Lymphoma. 2015;56:347–52.PubMedCrossRefGoogle Scholar
  130. 130.
    Fayette D, Gaherova L, Mocikova H, Markova J, Kozak T, Horacek J. Chemotherapy-related cognitive impairment in patients with hodgkin lymphoma - pathophysiology and risk factors. Klin Onkol. 2017;30:93–9.PubMedCrossRefGoogle Scholar
  131. 131.
    Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet. 2013;381:1943–55.PubMedCrossRefGoogle Scholar
  132. 132.
    Saultz JN, Garzon R. Acute myeloid leukemia: a concise review. J Clin Med. 2016;5.PubMedCentralCrossRefGoogle Scholar
  133. 133.
    Nabhan C, Rosen ST. Chronic lymphocytic leukemia: a clinical review. JAMA. 2014;312:2265–76.PubMedCrossRefGoogle Scholar
  134. 134.
    Apperley JF. Chronic myeloid leukaemia. Lancet. 2015;385:1447–59.PubMedCrossRefGoogle Scholar
  135. 135.
    Baccarani M, Castagnetti F, Gugliotta G, Palandri F, Rosti G. Treatment recommendations for chronic myeloid leukemia. Mediterr J Hematol Infect Dis. 2014;6:e2014005.PubMedPubMedCentralCrossRefGoogle Scholar
  136. 136.
    Davis AS, Viera AJ, Mead MD. Leukemia: an overview for primary care. Am Fam Physician. 2014;89:731–8.PubMedGoogle Scholar
  137. 137.
    Kanellopoulos A, Andersson S, Zeller B, Tamnes CK, Fjell AM, Walhovd KB, et al. Neurocognitive outcome in very long-term survivors of childhood acute lymphoblastic leukemia after treatment with chemotherapy only. Pediatr Blood Cancer. 2016;63:133–8.PubMedCrossRefGoogle Scholar
  138. 138.
    Ness KK, Hudson MM, Pui CH, Green DM, Krull KR, Huang TT, et al. Neuromuscular impairments in adult survivors of childhood acute lymphoblastic leukemia: associations with physical performance and chemotherapy doses. Cancer. 2012;118:828–38.PubMedCrossRefGoogle Scholar
  139. 139.
    Rajkumar SV, Kumar S. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc. 2016;91:101–19.PubMedPubMedCentralCrossRefGoogle Scholar
  140. 140.
    Al-Farsi K. Multiple myeloma: an update. Oman Med J. 2013;28:3–11.PubMedPubMedCentralCrossRefGoogle Scholar
  141. 141.
    Jaing TH. Complications of haematopoietic stem cell transplantation. ISBT Sci Ser. 2011;6:332–6.CrossRefGoogle Scholar
  142. 142.
    de Souza CV, Miranda EC, Garcia C Jr, Aranha FJ, de Souza CA, Vigorito AC. Functional evaluation indicates physical losses after hematopoietic stem cell transplantation. Rev Bras Hematol Hemoter. 2012;34:345–51.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Julie K. Silver
    • 1
    • 2
    Email author
  • Vishwa S. Raj
    • 3
    • 4
  • Eric M. Wisotzky
    • 5
    • 6
  1. 1.Department of Physical Medicine and RehabilitationHarvard Medical SchoolBostonUSA
  2. 2.Spaulding Rehabilitation, Massachusetts General and Brigham and Women’s HospitalsBostonUSA
  3. 3.Section of Rehabilitation, Department of Supportive CareThe Levine Cancer InstituteCharlotteUSA
  4. 4.Department of Physical Medicine and RehabilitationCarolinas Rehabilitation, Carolinas Medical Center, Carolinas Healthcare SystemCharlotteUSA
  5. 5.Rehabilitation MedicineGeorgetown University School of MedicineWashingtonUSA
  6. 6.Division of Rehabilitation Medicine, Cancer RehabilitationMedStar National Rehabilitation NetworkWashington, DCUSA

Personalised recommendations